TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 34888043
Drug: Combined Surgical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined Surgical and Injection of alcohol Treatment (COSIT), mean alcohol volume 72.0 mls, mean follow-up duration 16 months.
Study: 34888394
Drug: Serological testing
Normalized name: mumps skin test antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Serological testing for SARS-CoV-2 antibodies
Study: 34888394
Drug: Assessment of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Assessment of antibody effectiveness against variants
Study: 34889232
Drug: Imatinib mesylate
Normalized name: Imatinib Mesylate
DrugBank: Imatinib (DB00619)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Imatinib mesylate (200 mg/day and 400 mg/day) and pembrolizumab (200 mg every 3 weeks)
Study: 34889407
Drug: Novel therapies
Normalized name: Theraplex Eczema Therapy
DrugBank: Colloidal oatmeal (DB11286)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Novel therapies for acute myeloid leukemia (AML)
Study: 34889746
Drug: CBT-i Coach
Normalized name: iobenguane I-131
Approvals — FDA: no, EMA: no, PMDA: no
Description: CBT-i Coach app with adjunctive physical activity (PA)
Study: 34889776
Drug: Combined clinical
Normalized name: DuoCare Clinical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined clinical audits and low-dose, high-frequency (LDHF) in-service training for 6 months
Study: 34889775
Drug: Just-in-time adaptive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Just-in-time adaptive intervention group (Fitbit use, daily HRQOL reports, personalized push notifications for 3 months)
Study: 34889775
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (Fitbit use, daily HRQOL reports for 3 months without personalized feedback)
Study: 34890832
Drug: Ceritinib (≥
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ceritinib (≥ 300 mg)
Study: 34893524
Drug: Intravenous enadenotucirev
Normalized name: Enadenotucirev
DrugBank: Enadenotucirev (DB14873)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous enadenotucirev plus paclitaxel
Study: 34893524
Drug: Intraperitoneal enadenotucirev
Normalized name: Enadenotucirev
DrugBank: Enadenotucirev (DB14873)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intraperitoneal enadenotucirev monotherapy
Study: 34893771
Drug: Ciltacabtagene autoleucel
Normalized name: ciltacabtagene autoleucel
DrugBank: Ciltacabtagene autoleucel (DB16738)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ciltacabtagene autoleucel BCMA-targeted CAR-T cell therapy
Study: 34893952
Drug: All procedures
Normalized name: All Clear
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All procedures and treatments
Study: 34894221
Drug: RTS,S/AS01E vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: RTS,S/AS01E vaccine (3 priming doses)
Study: 34894221
Drug: RTS,S/AS01E vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: RTS,S/AS01E vaccine (annual booster dose)
Study: 34894221
Drug: RTS,S/AS01E vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: RTS,S/AS01E vaccine (2nd booster dose)
Study: 34894221
Drug: RTS,S/AS01E vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: RTS,S/AS01E vaccine (post-vaccination antibody response)
Study: 34894235
Drug: Inactivated SARS-CoV-2
Normalized name: Inactivated SARS-Cov-2 Vaccine
DrugBank: Inactivated SARS-CoV-2 Vaccine (Chinese Academy of Medical Sciences) (DB15863)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inactivated SARS-CoV-2 vaccine (CoronaVac), two doses administered at D0 and D28.
Study: 34894235
Drug: MMF monotherapy
Normalized name: MMF
DrugBank: Monomethyl fumarate (DB14219)
Approvals — FDA: no, EMA: no, PMDA: no
Description: MMF monotherapy in SSc patients.
Study: 34894681
Drug: JNK inhibitors
Approvals — FDA: no, EMA: no, PMDA: no
Description: JNK inhibitors with increased JNK1 bias, specifically a novel series of 2,4-dialkylamino-pyrimidine-5-carboxamides
Study: 34894681
Drug: Oral dosing
Normalized name: oral dosing devices
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral dosing of optimized JNK inhibitors
Study: 34895133
Drug: CGRP antibodies
Normalized name: digoxin antibodies Fab fragments Injection [DigiFab]
Approvals — FDA: no, EMA: no, PMDA: no
Description: CGRP antibodies treatment for 3 months
Study: 34895181
Drug: Vortioxetine 10-20
Normalized name: vortioxetine 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vortioxetine 10-20 mg over 12 weeks
Study: 34895190
Drug: Conservative treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conservative treatment or Open Reduction Internal Fixation (ORIF)
Study: 34895259
Drug: Single injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single injection of autologous cells
Study: 34895290
Drug: IVIG (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: IVIG (2 g/kg over 12-24 h with a maximum dose of 60 g) + aspirin (30 mg/kg/d) + prednisolone (2 mg/kg/d with a maximum dose of 60 mg tapered over 15 days after normalization of C-reactive protein concentration)
Study: 34895290
Drug: IVIG (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: IVIG (2 g/kg over 12-24 h with a maximum dose of 60 g) + aspirin (30 mg/kg/d)
Study: 34895750
Drug: Oral Anticoagulants
Normalized name: CPDA-1 Anticoagulant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral Anticoagulants (OACs)
Study: 34895750
Drug: Vitamin-K-Antagonists (VKAs)
Normalized name: Vitamin K antagonists
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin-K-Antagonists (VKAs)
Study: 34898139
Drug: LentiGlobin infusion
Normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: LentiGlobin infusion
Study: 34899612
Drug: 0.20 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.20 mg/kg biweekly PEG-rhGH
Study: 34899612
Drug: 0.20 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.20 mg/kg once-weekly PEG-rhGH
Study: 34899612
Drug: 0.25 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.25 mg/kg daily rhGH
Study: 34901464
Drug: Topical 0.5%
Normalized name: phenol topical 0.5% topical spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical 0.5% moxifloxacin plus topical placebo plus sham CXL
Study: 34901464
Drug: Topical 0.5%
Normalized name: phenol topical 0.5% topical spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical 0.5% moxifloxacin plus difluprednate 0.05% plus sham CXL
Study: 34901464
Drug: Topical 0.5%
Normalized name: phenol topical 0.5% topical spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical 0.5% moxifloxacin plus difluprednate 0.05% plus CXL
Study: 34901797
Drug: Ixazomib 4mg
Normalized name: IXAZOMIB 4MG CAP
DrugBank: Ixazomib (DB09570)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Ixazomib 4mg weekly for 24 weeks
Study: 34901797
Drug: Ixazomib treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ixazomib treatment
Study: 34901885
Drug: CoronaVac vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CoronaVac vaccine (3 μg in 0.5 mL, intramuscular injection) administered on day 0 and day 28
Study: 34902265
Drug: Grazoprevir (GZR)
DrugBank: Grazoprevir (DB11575)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Grazoprevir (GZR) 100 mg/Elbasvir (EBR) 50 mg daily for 12 weeks
Study: 34902800
Drug: Deep sedation
Normalized name: Deep Sea
Approvals — FDA: no, EMA: no, PMDA: no
Description: Deep sedation with 10 mg/kg/h Propofol and nasal oxygen 0.3 ml/kg/min
Study: 34903176
Drug: Crystalloids (80%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Crystalloids (80% balanced solutions)
Study: 34903251
Drug: Virtual reality-enhanced
Approvals — FDA: no, EMA: no, PMDA: no
Description: Virtual reality-enhanced personal construct therapy (PCT-VR)
Study: 34903251
Drug: Personal construct
Normalized name: Alstonia constricta bark extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Personal construct therapy (PCT)
Study: 34903452
Drug: RO4929097 in
Approvals — FDA: no, EMA: no, PMDA: no
Description: RO4929097 in combination with exemestane
Study: 34903842
Drug: CAN04 (1.0-10.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: CAN04 (1.0-10.0 mg/kg weekly)
Study: 34905086
Drug: Indocyanine green
Normalized name: Indocyanine Green
DrugBank: Indocyanine green (DB16024)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Indocyanine green (ICG) via mesenteric injection
Study: 34906130
Drug: Multi-disciplinary education
Normalized name: Parasedge Multi
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multi-disciplinary education program and Tai Chi exercise (Baduanjin), 4-week program with 2-h weekly talks and 1-h Tai Chi class.
Study: 34906208
Drug: Pharmacist-guided pre-emptive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmacist-guided pre-emptive pharmacogenetic testing to support clinical decision making on antidepressant selection and dosing.
Study: 34906208
Drug: Standard of
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard of care (antidepressant pharmacotherapy selected by the treating physician according to current treatment guidelines without knowledge of PGx test results).
Study: 34906248
Drug: Agitated local
Normalized name: docusate calcium / phenolphthalein Oral Capsule [Docal]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Agitated local anesthetic solution injected through the catheter with color Doppler ultrasound visualization.
Study: 34907058
Drug: Weekly self-reported
Normalized name: black imported fire ant allergenic extract
DrugBank: Solenopsis richteri (DB11026)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Weekly self-reported illness prevalence
Study: 34907058
Drug: Weekly self-reported
Normalized name: black imported fire ant allergenic extract
DrugBank: Solenopsis richteri (DB11026)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Weekly self-reported illness prevalence by sex
Study: 34907170
Drug: BNT162b2 (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: BNT162b2 (30 μg, 2 doses, 21 days apart)
Study: 34907192
Drug: Anti-CCR4 monoclonal
Normalized name: Anti-VEGF monoclonal antibody
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Anti-CCR4 monoclonal antibody mogamulizumab
Study: 34910393
Drug: Niraparib and
Normalized name: niraparib and abiraterone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Niraparib and bevacizumab maintenance therapy
Study: 34911359
Drug: Cabozantinib 60
Normalized name: cabozantinib 60 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cabozantinib 60 mg once daily for up to 18 months
Study: 34911463
Drug: REBOA (Resuscitative
Approvals — FDA: no, EMA: no, PMDA: no
Description: REBOA (Resuscitative endovascular balloon occlusion of the aorta) as adjunct treatment to advanced cardiac life support
Study: 34911667
Drug: Ruxolitinib 5
Normalized name: ruxolitinib 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ruxolitinib 5 mg BID, with optional up-titration to a maximum of 15 mg BID
Study: 34911817
Drug: RP-3500, a
Approvals — FDA: no, EMA: no, PMDA: no
Description: RP-3500, a novel ATR kinase inhibitor, administered orally.
Study: 34911956
Drug: Tetrathiomolybdate (TM),
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tetrathiomolybdate (TM), an orally bioavailable copper chelating agent.
Study: 34911992
Drug: Asunercept 200
Normalized name: Asunercept
DrugBank: Asunercept (DB15160)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Asunercept 200 mg/week plus standard RT/TMZ (Cohort 1)
Study: 34911992
Drug: Asunercept 400
Normalized name: Asunercept
DrugBank: Asunercept (DB15160)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Asunercept 400 mg/week plus standard RT/TMZ (Cohort 2)
Study: 34914545
Drug: Mosunetuzumab (group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mosunetuzumab (group B, step-up dosing)
Study: 34914826
Drug: Blinatumomab (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Blinatumomab (4 cycles administered every 3 months during the first year after HCT)
Study: 34915057
Drug: Re-treatment with
Normalized name: Re-Covr
Approvals — FDA: no, EMA: no, PMDA: no
Description: Re-treatment with ritlecitinib and brepocitinib
Study: 34915574
Drug: belimumab 10
Normalized name: Belimumab
DrugBank: Belimumab (DB08879)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: belimumab 10 mg/kg intravenous every 28 days for ≤7 years
Study: 34915909
Drug: Internet-delivered modular
Normalized name: DELIVER
Approvals — FDA: no, EMA: no, PMDA: no
Description: Internet-delivered modular intervention based on cognitive behavioral therapy (CBT) for 8 weeks
Study: 34916327
Drug: Perioperative intravenous
Normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Perioperative intravenous S(+)-ketamine plus conventional anaesthesia
Study: 34917565
Drug: High-dose gentamicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose gentamicin regimen
Study: 34917636
Drug: Implantation of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Implantation of microalgae (photosynthetic cells) for oxygen supply to tissues, specific dosage and duration not mentioned.
Study: 34918855
Drug: Diabetes treated
Normalized name: Diabetic Tussin EX
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diabetes treated with insulin
Study: 34919824
Drug: Sotorasib, oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sotorasib, oral administration once per day
Study: 34920345
Drug: Neither SXB
Normalized name: 2,2',3,3',4,4',5,5',6-nonachlorodiphenyl either
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neither SXB nor stimulants
Study: 34920345
Drug: Sodium oxybate
Normalized name: Sodium Oxybate
DrugBank: Sodium oxybate (DB09072)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sodium oxybate (SXB) with or without stimulants
Study: 34920739
Drug: Weight loss
Normalized name: HERBAL WEIGHT LOSS AID
Approvals — FDA: no, EMA: no, PMDA: no
Description: Weight loss with Metformin
Study: 34921324
Drug: Rapid 5-mL/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rapid 5-mL/kg body weight volume expansion
Study: 34921514
Drug: Romiplostim 1
Normalized name: ROMIPLOSTIM 125MCG/VIL INJ
Approvals — FDA: no, EMA: no, PMDA: no
Description: Romiplostim 1 μg/kg weekly for 2 weeks
Study: 34921514
Drug: Romiplostim 3
Normalized name: Romiplostim
DrugBank: Romiplostim (DB05332)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Romiplostim 3 μg/kg weekly for 2 weeks
Study: 34922614
Drug: DBS-based, drug
Approvals — FDA: no, EMA: no, PMDA: no
Description: DBS-based, drug resistance genotype-informed ART switching algorithm
Study: 34923853
Drug: Intracoronary autologous
Normalized name: Autologous cultured fibroblasts
DrugBank: Azficel-T (DB11051)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intracoronary autologous CD34+ cell therapy
Study: 34925553
Drug: DHP107 (oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: DHP107 (oral paclitaxel) 200 mg/m²
Study: 34926296
Drug: Tcm self-transfusion
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tcm self-transfusion combined with TACE treatment
Study: 34926296
Drug: TACE treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: TACE treatment alone (control group)
Study: 34926300
Drug: TACE combined
Approvals — FDA: no, EMA: no, PMDA: no
Description: TACE combined with endoscopic therapy
Study: 34926386
Drug: Smoking cessation
Normalized name: Zyban 150 MG Smoking Cessation 12 HR Extended Release Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Smoking cessation treatments
Study: 34926601
Drug: Shenfu Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Shenfu Injection
Study: 34926859
Drug: Tight glycemic
Normalized name: Glycerin
DrugBank: Glycerin (DB09462)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tight glycemic control (n = 72) via continuous intravenous insulin infusion maintaining blood glucose levels of 110-149 mg/dl
Study: 34926859
Drug: Conventional glycemic
Normalized name: Glycerin
DrugBank: Glycerin (DB09462)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional glycemic control (n = 72) via continuous intravenous insulin infusion maintaining blood glucose levels of 150-180 mg/dl
Study: 34927165
Drug: Telehealth physical
Normalized name: hypochlorite
DrugBank: Hypochlorite (DB11123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Telehealth physical therapy
Study: 34927165
Drug: In-person physical
Normalized name: hypochlorite
DrugBank: Hypochlorite (DB11123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: In-person physical therapy
Study: 34927307
Drug: Earlier locally
Normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Earlier locally ablative treatment of oligometastases
Study: 34928709
Drug: Nivolumab (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nivolumab (1 mg/kg) + Ipilimumab (3 mg/kg) for 2 doses, followed by computed tomography scan at week 6.
Study: 34928709
Drug: Nivolumab (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nivolumab (1 mg/kg) + Ipilimumab (3 mg/kg) for 3rd and 4th doses if no FATE at week 6, followed by Nivolumab monotherapy.
Study: 34928709
Drug: Nivolumab +
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nivolumab + Ipilimumab (standard treatment)
Study: 34930140
Drug: Tenofovir disoproxil
Normalized name: Tenofovir Disoproxil
DrugBank: Tenofovir disoproxil (DB00300)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tenofovir disoproxil fumarate (TDF) 300 mg once daily for 96 weeks
Study: 34930140
Drug: Entecavir (ETV)
Normalized name: Entecavir
DrugBank: Entecavir (DB00442)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Entecavir (ETV) 0.5 mg once daily
Study: 34930194
Drug: Exercise therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Exercise therapy + internet-delivered cognitive behavioral therapy (iCBT)
Study: 34930194
Drug: Exercise therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Exercise therapy + iCBT in combination with TKA
Study: 34930194
Drug: Usual treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Usual treatment with TKA and usual care physiotherapy
Study: 34930194
Drug: Exercise therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Exercise therapy + iCBT
Study: 34930356
Drug: High serum
Approvals — FDA: no, EMA: no, PMDA: no
Description: High serum choline concentrations (median 9.51 μg/mL)
Study: 34930356
Drug: Quartiles 2-4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quartiles 2-4 (serum choline ≥ 4.00 μg/mL)
Study: 34930356
Drug: Low serum
Normalized name: ZINC OXIDE 20 g in 100 mL TOPICAL CREAM [Sunceutical SPF 50 Mineral Glow Serum]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low serum choline concentrations (median 7.80 μg/mL)
Study: 34930428
Drug: Intensive blood
Normalized name: dragon's blood extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intensive blood pressure lowering (target systolic < 140 mmHg), glycemic control (target 6.1-7.8 mmol/L for non-diabetics and 7.8-10.0 mmol/L for diabetics), anti-pyrexia treatment (target body temperature ≤ 37.5 °C), reversal of anticoagulation (target INR < 1.5 within 1 hour)
Study: 34930734
Drug: Thoracoscopic surgery
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thoracoscopic surgery with additional treatment after bulla resection (specific details not provided).
Study: 34930734
Drug: Adverse outcomes
Normalized name: iodine
DrugBank: Iodine (DB05382)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Adverse outcomes correlated with various treatments (specific details not provided).
Study: 34930734
Drug: Feasibility of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Feasibility of treatment methods (specific details not provided).
Study: 34930741
Drug: Reperfusion treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reperfusion treatment at secondary hospitals
Study: 34930741
Drug: Fibrinolytic therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fibrinolytic therapy at secondary hospitals
Study: 34930741
Drug: Fibrinolytic therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fibrinolytic therapy timing
Study: 34930741
Drug: In-hospital death
Approvals — FDA: no, EMA: no, PMDA: no
Description: In-hospital death or treatment withdrawal
Study: 34932001
Drug: New integrated
Approvals — FDA: no, EMA: no, PMDA: no
Description: New integrated IT platform for medication reconciliation
Study: 34932284
Drug: AboBoNT-A (Dysport)
Normalized name: Dysport
DrugBank: DaxibotulinumtoxinA (DB17929)
Approvals — FDA: no, EMA: no, PMDA: no
Description: AboBoNT-A (Dysport) injections, mean doses 909-934 U between cycles 1 and 4
Study: 34932284
Drug: OnaBoNT-A (Botox)
Normalized name: botulinum toxin type A Injection [Botox]
Approvals — FDA: no, EMA: no, PMDA: no
Description: OnaBoNT-A (Botox) injections
Study: 34932284
Drug: IncoBoNT-A (Xeomin)
Normalized name: botulinum toxin type A Injection [Xeomin]
Approvals — FDA: no, EMA: no, PMDA: no
Description: IncoBoNT-A (Xeomin) injections
Study: 34932394
Drug: Balstilimab (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Balstilimab (3 mg/kg every 2 weeks) and Zalifrelimab (1 mg/kg every 6 weeks)
Study: 34932984
Drug: Dual GLP-1/GCG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dual GLP-1/GCG receptor agonist
Study: 34933701
Drug: Triclosan 0.5%
Normalized name: TRICLOSAN 0.5% SOLN,TOP
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triclosan 0.5% followed by 70% alcoholic solution
Study: 34933824
Drug: CRP measures
Normalized name: MEASLES VIRUS
Approvals — FDA: no, EMA: no, PMDA: no
Description: CRP measures collected at antimicrobial treatment start (V1), seven to 10 days later (V2), and two weeks after treatment end (V3).
Study: 34934447
Drug: Standard treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard treatment according to hospital protocols
Study: 34934864
Drug: Nivolumab (480
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nivolumab (480 mg intravenously every 4 weeks) + Stereotactic Radiosurgery (SRS)
Study: 34934987
Drug: Cabergoline (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cabergoline (0.5 mg) twice weekly + placebo daily for 6 months
Study: 34934987
Drug: Norethindrone acetate
Normalized name: Norethindrone Acetate
DrugBank: Norethisterone (DB00717)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Norethindrone acetate (5 mg/day) + placebo twice weekly
Study: 34935687
Drug: 100 mL
Normalized name: PVC IV Bag 100 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mL 4% gelatin intravenous boluses (five sequential boluses)
Study: 34935687
Drug: 200 mL
Normalized name: Bag Top-Fill, 1200 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mL fluid challenge (FC)
Study: 34935913
Drug: SARS-CoV-2 mRNA
Normalized name: SARS-CoV-2 mRNA
Approvals — FDA: no, EMA: no, PMDA: no
Description: SARS-CoV-2 mRNA vaccine (two doses of Pfizer-BioNTech)
Study: 34936697
Drug: Obinutuzumab plus
Normalized name: Obinutuzumab
DrugBank: Obinutuzumab (DB08935)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Obinutuzumab plus lenalidomide (GALEN combination)
Study: 35536314
Drug: Elexacaftor/Tezacaftor/Ivacaftor Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Elexacaftor/Tezacaftor/Ivacaftor Therapy
Study: 34937189
Drug: Piperacillin-Tazobactam continuous
Normalized name: piperacillin / tazobactam
Approvals — FDA: no, EMA: no, PMDA: no
Description: Piperacillin-Tazobactam continuous infusion